Shared on 07 Aug 25

Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.

Read more

0 votesShare

Shared on 01 May 25

Fair value Increased 39%

Read more

0 votesShare

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Decreased 2.97%

AnalystConsensusTarget has increased revenue growth from 12.0% to 15.6%, decreased profit margin from 4.7% to 0.0% and increased future PE multiple from 119.2x to 36440.9x.

Read more

0 votesShare

Shared on 26 Mar 25

Fair value Decreased 1.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 19 Mar 25

Fair value Decreased 19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 11 Mar 25

Fair value Increased 11%

Read more

0 votesShare